Frequency of mutations in rifampicin and isoniazid resistant isolates of M. tuberculosis: an analysis from Central India

Desikan, Prabha; Kharate, Atul; Panwalkar, Nikita; Khurana, Jyoti; Mirza, Shaina Beg; Chaturvedi, Aparna; Varathe, Reeta; Chourey, Manju; Kumar, Pradeep; Doshi, N; Pandey, Manoj

doi:10.11599/germs.2016.1096

Cited by 13 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the 56 cases of INH resistance mutations, 30 were katG 315 AGC → ACC (53.6%), and 26 were inhA -15 (C → T) (46.4%). Mutation rates of 14–17% and 22–24% have been reported for katG 315 AGC → ACC and inhA -15 (C → T), respectively [ 28 , 34 ]; these values are very different from our results. This discrepancy may be caused by regional differences [ 2 ].…”

Section: Discussioncontrasting

confidence: 99%

“…The main mutation in rpoB was the Ser531Leu mutation, which occurred in our samples, followed by mutations of residue 526. In similar previous reports, the 531 mutation was the most commonly detected, followed by the 526 mutation [ 28 – 32 ]. The results of our experiment revealed strains with mutations at three loci that were resistant to RFP (i.e., rpoB Asp516Tyr plus Gln513Leu plus Leu511Pro).…”

Section: Discussionsupporting

confidence: 72%

See 1 more Smart Citation

GeneChip analysis of resistant Mycobacterium tuberculosis with previously treated tuberculosis in Changchun

Zhang

Ren

Sun³

et al. 2018

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundWith the widespread use of rifampicin and isoniazid, bacterial resistance has become a growing problem. Additionally, the lack of relevant baseline information for the frequency of drug-resistant tuberculosis (TB) gene mutations is a critical issue, and the incidence of this infection in the city of Changchun has not investigated to date. However, compared with the slow traditional methods of drug susceptibility testing, recently developed detection methods, such as rifampicin and isoniazid resistance-related gene chip techniques, allow for rapid, easy detection and simultaneous testing for mutation frequency and drug resistance.MethodsIn this study, the rifampicin and isoniazid resistance-related gene mutation chip method was employed for an epidemiological investigation. To assess the gene mutation characteristics of drug-resistant TB and evaluate the chip method, we tested 2143 clinical specimens from patients from the infectious diseases hospital of Changchun city from January to December 2016. The drug sensitivity test method was used as the reference standard.ResultsThe following mutation frequencies of sites in the rifampicin resistance gene rpoB were found: Ser531Leu (52.6%), His526Tyr (12.3%), and Leu511Pro (8.8%). The multidrug-resistance (MDR)-TB mutation frequency was 34.7% for rpoB Ser531Leu and katG Ser315Thr, 26.4% for rpoB Ser531Leu and inhA promoter − 15 (C → T), and 10.7% for rpoB His526Tyr and katG Ser315Thr. In addition, drug susceptibility testing served as a reference standard. In previously treated clinical cases, the sensitivity and specificity of GeneChip were 83.1 and 98.7% for rifampicin resistance, 79.9 and 99.6% for isoniazid resistance, and 74.1 and 99.8% for MDR-TB.ConclusionsOur experimental results show that the chip method is accurate and reliable; it can be used to detect the type of drug-resistant gene mutation in clinical specimens. Moreover, this study can be used as a reference for future research on TB resistance baselines.Electronic supplementary materialThe online version of this article (10.1186/s12879-018-3131-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 72%

GeneChip analysis of resistant Mycobacterium tuberculosis with previously treated tuberculosis in Changchun

Zhang

Ren

Sun³

et al. 2018

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…A third type of mutation H526Y found in new cases (4.1%) but not detected in default and failure cases, whereas H526D was detected only in the failure cases and the chance of this mutation becomes high in retreated patients. These mutations are also reported in another study with different frequencies (Desikan et al, 2016;Tadesse et al, 2016;). The difference in frequencies can occur geographically according to the population, circulating strain pattern and poor management of MDR-TB.…”

Section: Discussionsupporting

confidence: 74%

Variations in rifampicin and isoniazid resistance associated genetic mutations among drug naïve and recurrence cases of pulmonary tuberculosis

Kabir

Junaid

Rehman

2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Background: The resistance to first-line drugs can increase the risk of treatment failure and development of resistance to other anti-TB drugs. In TB endemic settings, a considerable rate of recurrence cases exhibited each, year which adds significant burden to the prevalence of disease worldwide. Methods: A total of 562 sputum samples were collected from presumptive positive clinical cases of MDR tuberculosis. Treatment history and demographic data of the patients were obtained after informed consent. Xpert MTB/RIF assay was performed for simultaneous detection of MTB and rifampicin resistance. The mutation patterns of isoniazid and rifampicin were observed after multiplex PCR and reverse hybridization by Genotype 1 MTBDRplus version 2.0 assay. Results: A total of 73 of 97 cases (75.2%) of treatment failure were found positive for MDR-TB, whereas 79.6% newly diagnosed and 72.9% default cases were MDR in our isolates. The mutation of rpoB S531L was slightly higher in new treatment cases (89.3%) as compared to the default (80.4%) and failure cases (84.8%), whereas rpoB D516V mutation was more prevalent in default cases (19.6%) with complete absence of rpoB 526 mutation, which was observed in the other two types of cases. The mutation pattern of katG resistance differed among drug naïve and recurrence cases. The resistance in newly diagnosed cases was mostly conferred by katG 315 (49.1%) whereas in default (70.8%) and failure cases (63.3%) isoniazid resistance was commonly associated with katG S315T1 mutation. Mutations in inhA promoter region occurred at nucleotide position À8 and À15. In new cases the rate of mutation of C-15T was 3.7% and T-8A was 1.5% while in treatment failure cases the frequency for C-15T and T-8C was 2.5 and 3.8% respectively. However, no inhA promoter region mediated mutations were detected in default treatment cases. Conclusion: Retreated cases are at more risk of developing hot spot mutations. An unusual difference in mutation pattern was determined in naïve and recurrence cases. Some mutations were exclusively associated with the retreatment of 35anti-TB drugs which suggest the increased risk of resistance with poor treatment outcome.

show abstract

“…Studies from Vietnam 20 showed 50% association of S531L mutation with rifampicin resistance. Studies from Punjab 9 and Central India 18 showed 58.4% and 65.88% association of S531L mutation with rifampicin resistance respectively. Isoniazid resistance due to katG gene mutation was documented in 72.58% INH resistant study isolates in agreement with studies from Punjab 93.2%, 9 France 62.5%.…”

Section: Discussionmentioning

confidence: 96%

Drug-resistant Tuberculosis: First Line Drug Resistance Pattern among Mycobacterium Tuberculosis Strains Isolated from a Reference Laboratory in Kerala State, India

Murthy¹,

Nair²,

Ramya³

et al. 2021

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

Resistance to antimycobacterial agents consistently remains a major obstacle to end TB in India. Geographical prevalence data regarding drug-resistant evolutionary genetics of M. tuberculosis (MTB) remains sparse in India. Our objective was to determine the genotypic drug resistance mutation pattern for Rifampicin and Isoniazid of MTB isolates to gain an understanding of the prevailing molecular epidemiology of drug-resistant tuberculosis. In this study 2528 M. tuberculosis DNA isolates from presumptive DRTB suspects received at the nodal TB reference laboratory in Kerala were tested for Rifampicin and Isoniazid resistance by sequence-based diagnostic Line Probe assay (LPA). Geographical prevalence and associations of rpoB, katG, inhA resistance codons was analyzed from January 2019 to March 2020. Among the 2528 DNA samples subjected for Rifampicin and Isoniazid resistance determination by LPA, 146 (5.8%) isolates were resistant to both drugs. Isoniazid mono-resistance was found in 164 (6.5%) and Rifampicin mono-resistance in 38 (1.5%) isolates. The most frequent rpoB mutation was S531L (60.32%) followed by S531W/L533P mutations seen in 8.15% of the isolates. S315T1 KatG mutation was seen in 97.33% of Isoniazid resistant isolates. 84.68% isolates with rpoB S531L mutation were found to be multidrug-resistant. 82.9% of isolates with rpoB S531L mutation showed katG S315T1 mutation. Mono isoniazid-resistant isolates were significantly higher compared to mono rifampicin-resistant isolates among the DNA isolates studied in our region. The molecular epidemiological pattern most frequently associated with multidrug resistance was rpoB S531L which was significantly associated with the co-presence of S315T1 mutation.

show abstract

Frequency of mutations in rifampicin and isoniazid resistant isolates of M. tuberculosis: an analysis from Central India

Cited by 13 publications

References 12 publications

GeneChip analysis of resistant Mycobacterium tuberculosis with previously treated tuberculosis in Changchun

GeneChip analysis of resistant Mycobacterium tuberculosis with previously treated tuberculosis in Changchun

Variations in rifampicin and isoniazid resistance associated genetic mutations among drug naïve and recurrence cases of pulmonary tuberculosis

Drug-resistant Tuberculosis: First Line Drug Resistance Pattern among Mycobacterium Tuberculosis Strains Isolated from a Reference Laboratory in Kerala State, India

Contact Info

Product

Resources

About